The role of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) in cardiovascular disease

Reviews on Recent Clinical Trials

Volumn 6, Issue 2, 2011, Pages 108-113

  Ikonomidis, Ignatios ^a   Michalakeas, Christos A ^a   Lekakis, John ^a   Parissis, John ^a   Anastasiou Nana, Maria ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Cardiovascular disease; Inflammatory biomarkers; Lp PLA2; PAF AH

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATORVASTATIN; C REACTIVE PROTEIN; DARAPLADIB; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; VARESPLADIB;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FOOD DRUG INTERACTION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAXIMUM PLASMA CONCENTRATION; MORTALITY; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; TREATMENT OUTCOME; ULCERATIVE COLITIS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS;

EID: 79953865386     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488711795177903     Document Type: Review

References (45)

1. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996; 124 (Suppl): S1-S9.
2. Ikonomidis I, Lekakis J, Revela I, Andreotti F, Nihoyannopoulos P. Increased circulating C-reactive protein and macrophage-colony stimulating factor are complementary predictors of long-term outcome in patients with chronic coronary artery disease. Eur Heart J 2005; 26: 1618-24.
3. Pillarisetti S, Alexander CW, Saxena U. Atherosclerosis--new targets and therapeutics. Curr Med Chem Cardiovasc Hematol Agents 2004; 2 (4): 327-34.
4. McCullough PA. Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target? Curr Atheroscler Rep 2009; 11 (5): 334-7.
5. Asano K, Okamoto S, Fukunaga K, et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun 1999; 261: 511-4.
6. Nakajima K, Murakami M, Yanoshita R, et al. Activated mast cells release extracellular type platelet-activating factor acetylhydrolase that contributes to autocrine inactivation of platelet-activating factor. J Biol Chem 1997; 272: 19708-13.
7. Laine P, Kaartinen M, Penttila A, et al. Association between myocardial infarction and the mast cells in the adventitia of the infarctrelated coronary artery. Circulation 1999; 99: 361-9.
8. Chen CH. Platelet activating factor acetylhydrolase: is it good or bad for you? Curr Opin Lipidiol 2004; 15: 337-41.
9. Hakkinen T, Luoma JS, Hiltunen MO, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999; 19: 2909-17.
10. Daniels LB, Laughlin GA, Sarno MJ, Bettencourt R, Wolfert RL, Barrett-Connor E. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol 2008; 51: 913-9.
11. Macphee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999; 338: 479-87.
12. Tselepis AD, Chapman MJ. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase. Atheroscler Suppl 2002; 3: 57-68.
13. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005; 25: 923-31.
14. Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26(11): 2523-9.
15. Rosenson RS, Gelb MH. Secretory phospholipase A2: A multifaceted family of proatherogenic enzymes. Curr Cardiol Rep 2009; 11(6): 445-51.
16. Tsimikas S, Willeit J, Knoflach M, et al. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J 2009; 30: 107-15.
17. Kim JY, Hyun YJ, Jang Y, et al. Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress in a case-control study. Am J Clin Nutr 2008; 88: 630-7.
18. Shepherd J, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-07.
19. Packard CJ, O'reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 2000; 343: 1148-55.
20. Ballantyne C, Hoogeveen R, Bank H, et al. Lipoprotein-associated phospholipase A2, high sensitive C-reactive protein and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109: 837-42.
21. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004; 110: 1903-8.
22. Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005; 111: 570-5.
23. Daniels LB, Laughlin GA, Sarno MJ, et al. Lipoprotein-associated phospholipase a2 is an independent predictor of incident coronary heart disease in an apparently healthy older population. The rancho bernardo study. JACC 2008; 51: 913-9.
24. Mockel M, Danne O, Muller R, et al. Development of an optimized biomarker strategy for early risk assessment of patients with acute coronary syndromes. Clin Chim Acta 2008; 393: 103-9.
25. 2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscl Thromb Vasc Biol 2006; 26: 1586-93.
26. Sabatine MS, Morrow DA, O'Donoghue M, et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscl Thromb Vasc Biol 2007; 27: 2463-9.
27. Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase a2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008; 101[suppl]: 51F-57F.
28. Ridker PM, Cannon CP, Morrow D, et al. C-Reactive Protein Levels and Outcomes after Statin Therapy. N Engl J Med 2005; 352: 20-8.
29. Ridker PM, Danielson E, Fonseca F, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med 2008; 359: 2195-207.
30. Ikonomidis I, Lekakis JP, Nikolaou M, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 2008; 117(20): 2662-9.
31. Caslake MJ, Packard CJ. Lp-PLA2 and cardiovascular disease. Curr Opin Lipidol 2003; 14: 347-52.
32. Tsimihodimos V, Karabina SA, Tambaki AP, et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 2002; 22: 306-11.
33. Tsimihodimos V, Kakafika A, Tambaki AP, et al. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res 2003; 44: 927-34.
34. Tomita Y, Kuwabara K, Furue S, et al. Effect of a selective inhibitor of secretory phospholipase A2, S-5920/LY315920Na, on experimental acute pancreatitis in rats. J Pharmacol Sci 2004; 96(2): 144-54.
35. Bradley JD, Dmitrienko AA, Kivitz AJ, et al. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol 2005; 32(3): 417-23.
36. Zeiher BG, Steingrub J, Laterre, et al. PFLY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis. Crit Care Med 2005; 33(8): 1741-8.
37. Leite JO, Vaishnav U, Puglisi M, et al. A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs. BMC Cardiovasc Disord 2009; 9: 7.
38. Karakas M, Koenig W. Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease. IDrugs 2009; 12(9): 585-92.
39. Suckling KE. Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic. Expert Opin Investig Drugs 2009; 18(10): 1425-30.
40. Riley RF, Corson MA. Darapladib, a reversible lipoproteinassociated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease. IDrugs 2009; 12(10): 648-55.
41. Wilensky RL, Shi Y, Mohler ER, et al. Inhibition of lipoproteinassociated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008; 14: 1059-66.
42. Mohler ER, Ballantyne CM, Davidson MH, et al, for the Darapladib Investigators. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008; 51: 1632-41.
43. Serruys PW, García-García HM, Buszman P, et al. for the Integrated Biomarker and Imaging Study-2 Investigators. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008; 118: 1172-82.
44. The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial (STABILITY). Study NCT00799903, Information provided by GlaxoSmithKline. Last Updated: July 15, 2010. Available from: http://clinicaltrials.gov/ct2/show/record/NCT00799903.
45. The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial (SOLID-TIMI 52). Study NCT01000727, Information provided by GlaxoSmithKline. Last Updated: June 29, 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01000727?term=SOLID+TI MI+52&rank=1.